Chemomab Therapeutics Ltd... (CMMB)
1.09
-0.04 (-3.54%)
At close: Mar 31, 2025, 12:56 PM
-3.54% (1D)
| Bid | 1.07 |
| Market Cap | 1.03M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -699.42K |
| EPS (ttm) | -0.86 |
| PE Ratio (ttm) | -1.27 |
| Forward PE | -59.71 |
| Analyst | Strong Buy |
| Ask | 1.11 |
| Volume | 283,898 |
| Avg. Volume (20D) | 375,511 |
| Open | 1.06 |
| Previous Close | 1.13 |
| Day's Range | 0.92 - 1.11 |
| 52-Week Range | 0.58 - 2.55 |
| Beta | 0.49 |
About CMMB
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and cha...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 12, 2019
Employees 20
Stock Exchange NASDAQ
Ticker Symbol CMMB
Website https://www.chemomab.com
Analyst Forecast
According to 2 analyst ratings, the average rating for CMMB stock is "Strong Buy." The 12-month stock price forecast is $9, which is an increase of 727.05% from the latest price.
Stock Forecasts9 months ago
-11.63%
Chemomab Therapeutics shares are trading lower. Th...
Unlock content with
Pro Subscription
10 months ago
+11.72%
Chemomab Therapeutics shares are trading higher after the company reported a year-over-year increase in Q1 GAAP EPS results.
